Nipamovir
Nipamovir is a nitroimidazole prodrug. Nipamovir shows comparable antiviral activity to SAMT-247 (HY-102077) and NS-1040 in both cellular assays and a human ex vivo model of HIV infection, along with low toxicity. Nipamovir has EC50 values of 3.64±3.28 and 3.23±2.81 μM for CEM-SS/HIV-1RF and hPBMC/HIV-192HT599, respectively[1].
Product Specifications
CAS Number
[2651908-78-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HIV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/nipamovir.html
Purity
98.60
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NCCC(N)=O)C1=C(SC2=C([N+]([O-])=O)N=CN2C)C=CC=C1
Molecular Formula
C14H15N5O4S
Molecular Weight
349.37
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
IKBKB (Inhibitor of kappa Light Polypeptide Gene Enhancer in B-Cells, Kinase beta, FLJ40509, IKK-beta, IKK2, IKKB, MGC131801, NFKBIKB) (APC)